5.50 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||5.24 x 1200|
|Ask||6.00 x 1400|
|Day's Range||5.23 - 5.83|
|52 Week Range||5.15 - 25.10|
|Beta (3Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.13|
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Endologix (ELGX) delivered earnings and revenue surprises of 53.75% and 0.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, as well as the right of first negotiation for future product offerings by Endologix. “We are excited to partner with Boston Scientific to bring next-generation abdominal aortic aneurysm solutions to patients in China,” said John Onopchenko, Chief Executive Officer of Endologix, Inc. “China is one of the largest and fastest-growing EVAR markets in the world, representing an exciting market opportunity for Endologix.
Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to commence a new pivotal study to evaluate the safety and effectiveness of the Nellix Chimney EndoVascular Aneurysm Sealing System ("ChEVAS") for the endovascular treatment of complex abdominal aortic aneurysms (“AAA”). The ChEVAS system is an endovascular abdominal aortic aneurysm therapy designed to combine the Nellix 3.5 endograft with parallel visceral stents to enable treatment of patients with juxta-renal, para-renal, and suprarenal AAA. John Onopchenko, Chief Executive Officer for Endologix, commented, "We are pleased to receive IDE approval from the FDA to begin this study, which will recruit 120 patients with complex AAA in up to 50 centers, both in the USA and internationally.
Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019.
Endologix (ELGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 877-407-9716 (domestic) or +1 201-493-6779 (international) and refer to the passcode 13692632.
Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”). The awards were approved by the Company’s Compensation Committee, which is comprised of independent directors, on June 12, 2019 and July 3, 2019, respectively, as inducements material to the Awardees’ entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grants to the Awardees consist of options (“Options”) to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and restricted stock units (“RSUs” and together with the Options, the “Awards”).
Endologix, Inc. (NASDAQ:ELGX) shareholders should be happy to see the share price up 15% in the last month. But that...
Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 2019 BMO Prescriptions for Success Healthcare Conference at 2:00 p.m.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...
Endologix® Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been reinstated by GMED, the EU Notified Body for the Nellix System. The reinstatement followed an assessment of clinical evidence. “We continue to believe that the Nellix System has the potential to transform the treatment of patients with infra-renal abdominal aortic aneurysms,” said Matt Thompson MD, Chief Medical Officer of Endologix, Inc. “This therapy continues to generate positive results when used in patients that conform to the anatomical indications for use.
Zacks.com featured highlights include: Avis, California Resources, Brinker, Endologix and Brookdale
In view of the ongoing uncertainties it is in the best interest of investors to seek guidance from brokers for designing a winning portfolio of stocks.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...
Endologix (ELGX) delivered earnings and revenue surprises of 28.21% and 4.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Irvine, California-based company said it had a loss of $2.12. Losses, adjusted for non-recurring costs and restructuring costs, were $1.12 per share. The results exceeded Wall ...
Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2019.
Endologix (ELGX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 855-327-6838 (domestic) or 631-891-4304 (international) and refer to the passcode 10006610.
When I am analyzing a company to see if it could potentially be a good long-term investment, I always research what the insiders are doing. It goes without saying that they probably have a much better idea of what is happening in the company than most analysts and they certainly know more about it than I do. I especially like to see what they are doing after their company's stock has fallen dramatically.I am not implying that there is anything illicit or illegal going on. When an insider wants to buy or sell their company's stock they can, as long as they follow very strict procedures. For instance, they have to file their intent to buy or sell with the SEC, and they are subject to "blackout periods," which are times in which they cannot trade the stock.For example, an insider may be prohibited from buying or selling the stock in the thirty days before or after the earnings release is due to be reported.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhat's more, an officer or a director of a company may decide to sell their stock for many reasons. They could need to raise money for tuitions, mortgages, weddings or even divorce settlements. But the insiders only buy for one reason: if they believe that the stock is undervalued and that it will eventually trade at a higher price where they can make a profit. * 7 Mid-Cap Stocks to Find the Market's Sweet Spot The following stocks have experienced such insider buying, and as such, are worthy of further inspection: EQT Corp (EQT) Click to Enlarge EQT Corp. (NYSE:EQT, $21.61) deals with natural gas in the Appalachian area. You may have never heard of EQT corporation, but you have probably used their products, as it's the largest producer of natural gas in the United States.Insider buying at the EQT Corporation has been prolific. The President, Robert McNally, bought almost 21,000 shares on March 29 at an average price of $20.80. He spent $200,000. The Executive Vice President, Erin Centofanti, bought almost 8,000 shares on March 29 at $20.83. Sue Smith, the CFO, paid $19.75 for 6,000 shares on March 14.Back in February Jonathon Lushko, the General Counsel and a Senior VP of the company, purchased almost 8,000 shares on the open market at an average price of $19.04. That is an investment of almost $150,000. In addition, the Senior VP of Human Resources, David Smith, invested more than $300,000 when he purchased 16,800 shares of the stock at an average price of $19.06.It is always interesting to see if and when the insiders buy their company stock after it has sold off significantly. In this case, the price of EQT has fallen about 50% in less than a year. This could be the reason why these insiders decided to invest. The stock is currently trading around $21.61, so they have already profited nicely.The analysts on Wall Street seem to like this stock as well. According to MarketWatch, twenty firms follow it on a research basis. Two of them have it rated as overweight, eleven have a buy rating on it, six rate it as holds and there's just one sell recommendation. The average target price is $25.40, which is about 20% higher than where it is currently trading. RumbleOn (RMBL) Click to Enlarge RumbleOn, Inc. (NASDAQ:RMBL, $5.60) is an e-commerce platform that is designed to help consumers and dealers finance, buy and sell used cars.Denmar Dixon is a member of the Board of Directors of RumbleOn. Mr. Dixon purchased 50,000 shares at $4.76 in early April. He also made considerable purchases early last year before the stock rallied. Back then, it was trading around the same levels that it currently is.The stock more than doubled when it traded above $10 in September and October. Mr. Dixon must have been feeling pretty good. But then it went into freefall and lost more than 50% of its value by December. * 10 Stocks That Are Screaming Buys Right Now This company is followed on a research basis by six companies. The average rating is a buy and the average target price is $9.90, which is more than 40% higher than where it is currently trading. Endologix (ELGX) Click to Enlarge Endologix, Inc. (NASDAQ:ELGX, $6.99) performs research and development and manufactures devices that treat aortic diseases. Its portfolio of products includes AFX Endovascular AAA System, Nellix and Ovation.On April 3, it was announced that the CEO, John Onopchenko, invested $200,000 when he purchased just over 30,000 shares. This increased his personal holdings in the stock by almost 40%. The CFO, Vaseem Mahboob, invested $100,000 of his personal money when he acquired 15,000 shares. In addition, two of the company's directors bought and additional 25,000 shares. These shares were all purchased at an average price of $6.61.Endologix has lost more than 90% of its value over the past year. They have recently announced that they are going to restructure their debt. This could be a good thing, or it could be a sign of desperation. The insider buying may mean that the insiders think that the restructuring will work.According to MarketWatch, nine firms follow this stock on a research basis. One has a buy rating on it, one has a sell rating and the other nine consider it a hold. The average target price is $10.30, which is significantly higher than where it is currently trading. This makes me wonder why seven firms have a hold on a stock that they feel is undervalued by 35%. Walgreens (WBA) Click to Enlarge You've probably been to Walgreens (NYSE:WBA, $54.69). It's one of the largest pharmacies in the country, with retail and pharmacy operations both domestically and on an international stage. The company was founded in 1901 and is headquartered in Deerfield, IL.Co-Chief Operating Officer Ms. Omella Barra may think that the recent selling in WBA is overdone. She invested nearly $1 million of her own money when she purchased 18,000 shares at an average price of $54.50 on April 3.WBA has had some issues lately. The company has sold off considerably because the two most recent earnings releases disappointed investors. The stock has fallen about 35% since November and it is trading at the lowest level that it has been at since 2014. Time will tell if there will be more insider buying. * The 7 Best Long-Term Stocks for 2019 And Beyond This company is widely followed on Wall Street. According to Marketwatch.com, 26 firms cover it. The average analyst rating is a hold and the average price target is $62.50. It is currently trading just under $55. Chaparral Energy (CHAP) Click to Enlarge Chaparral Energy, Inc. (NYSE:CHAP, $5.58) is in the natural gas and oil exploration and production (E&P) business. Specifically, CHAP makes its money on deposits of Stack, Meramec and Osage, Oswego and Woodford located in Oklahoma and the Texas Panhandle. Founded by Mark A. Fischer and Charles A. Fischer in April 1988, Chaparral Energy is headquartered in Oklahoma City, OK.The CEO of the company, K. Earl Reynolds, purchased 7,100 shares of CHAP on March 29th at an average price of $4.64. A large institutional holder, Strategic Value Partners, also recently acquired 900,000 shares at a price of $4.45.The stock has fallen by more than 75% over the past year. Mr. Reynolds and the portfolio managers at Strategic Value Partners must believe that the stock is very attractive at these prices.Wall Street likes this stock as well. It is followed by four firms that follow the company on a research basis. The average rating is a buy and the average target price is $18.38. That is more than 300% higher than where it is currently trading.As of this writing, Mark Putrino did not hold any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post 5 Stocks to Profit From (Legal) Insider Buying Signals appeared first on InvestorPlace.